Moderna Inc. weekly uptrend opportunity based On 1.00 Lot Calculation:
- Moderna, Inc. a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. They are one of the largest suppliers of Covid- 19 vaccine in the world, holding an efficacy rate of around 95%.
- REVENUE TO RISE IN 2021 in 2022: Moderna Inc. said it has reached $18.4 billion worth of signed agreements for its Covid-19 vaccine in 2021. Its Covid-19 vaccine sales have the potential to grow even further as the biotech continues to negotiate supply agreements with governments around the world.
- COVID- 19 VACCINE PRODUCTION AND DELIVERY TO RISE: The vaccine maker aims to deliver as many as 1 billion doses in 2021, and 1.4 billion doses in 2022. The company raised the lower end of its 2021 projection from 600 million doses to 700 million doses. Moderna said it had completed manufacturing doses of a new version of its Covid-19 vaccine modified to target the South Africa strain, or B.1.351, and shipped it to researchers at the National Institutes of Health for clinical study.
- EVENT: MODERNA TESTS COVID- 19 VACCINE ON POPULATION BELOW 17 YEARS OF AGE. FIRST UPDATES ARE EXPECTED SOON: Moderna launched a trial at 12 to 17 years old. 3000 are expected to be enrolled. The updated data is expected to be released mid- year 2021. The largest population on Earth (around 30%) is below 17 so if all goes well this could prove to be a big market for Moderna. Moderna has also begun (March 16) testing its Covid-19 vaccine in children aged 6 months to 11 years of age.
- BOOSTER SHOTS: The company said it has dosed the first participants in a study evaluating its new coronavirus booster-vaccine candidates. The company is testing whether a booster dose could provide even more protection, particularly to people who are more vulnerable to severe forms of the disease. Should the booster vaccines prove safe and provide an additional layer of protection against coronavirus variants, they could become an important weapon in the global battle against COVID-19. In the process, they would also give Moderna a significant new source of recurring revenue, particularly if the booster shots are needed on an annual basis or every six months.
Moderna Inc., (#MODERNA) March 26, 2021
Current Price: 131
|
Moderna Inc. |
Weekly |
|
Trend direction |
|
|
170 |
|
|
160 |
|
|
150 |
|
|
113 |
|
|
105 |
|
|
100 |
Example of calculation base on weekly trend direction for 1.00 Lot*
|
MODERNA INC. |
||||||
|
Pivot Points |
||||||
|
Profit or loss in $ |
39,000.00 |
29,000.00 |
19,000.00 |
-18,000.00 |
-26,000.00 |
-31,000.00 |
|
Profit or loss in €** |
33,096.57 |
24,610.27 |
16,123.97 |
-15,275.34 |
-22,064.38 |
-26,307.53 |
|
Profit or loss in £** |
28,307.23 |
21,048.96 |
13,790.70 |
-13,064.87 |
-18,871.49 |
-22,500.62 |
|
Profit or loss in C$** |
49,009.74 |
36,443.14 |
23,876.54 |
-22,619.88 |
-32,673.16 |
-38,956.46 |
* 1.00 lot is equivalent of 1000 units
** Calculations for exchange rate used as of 13:11 (GMT) 26/03/2021
Fortrade recommends the use of Stop-Loss and Take-Profit, please speak to your Client Manager regarding their use.
*** You may wish to consider closing your position in profit, even if it is lower than suggested one
**** Trailing stop technique can protect the profit – Ask your Client Manager for more details